Introduction {#s1}
============

G protein-coupled receptors (GPCRs) are versatile signaling proteins that mediate diverse cellular responses. With over 800 members, GPCRs constitute the largest family of integral membrane proteins in human genome and represent roughly half of all drug targets in modern medicine ([@bib17]).

The human β~2~-adrenergic receptor (β~2~AR) is one of the best-characterized GPCRs. It is expressed in pulmonary and cardiac myocyte tissues and is a therapeutic target for asthma and heart failure ([@bib39]). The functional diversity of β~2~AR is associated with its structural dynamics ([@bib44]; [@bib30]). Recently found structures of β~2~AR in the inactive and active states have provided valuable insights into the structure-function relationship of β~2~AR ([@bib7]; [@bib20]; [@bib60]). Subsequent biophysical and biochemical studies have provided direct evidences of multiple distinct conformational states for specific GPCRs, such as β~2~AR ([@bib44]; [@bib30]; [@bib50]). Meanwhile, molecular dynamics (MD) simulations have depicted the dynamic behavior of β~2~AR and have significantly enhanced our understanding of the activation mechanism of GPCRs ([@bib12]; [@bib53]; [@bib13]). Intriguingly, it is now evident that the activation of GPCRs is modulated by lipids ([@bib51]).

The lipid raft concept ([@bib40]; [@bib1]) essentially states that cell membranes include functional nanoscale domains where the function emerges from proteins whose structure and activation are modulated by lipids. However, despite a large body of research data, direct substantiation of lipid-induced protein modulation remains limited. Contreras et al. showed that the COPI machinery protein p24 is recognized by a specific sphingomyelin ([@bib8]). Coskun et al. showed that monosialoganglioside GM3 influences the activation of the epidermal growth factor receptor ([@bib9]), however the mechanism is not known. Lipid modulation also holds to GPCRs ([@bib51]; [@bib48]; [@bib11]) in particular through cholesterol ([@bib51]; [@bib54]; [@bib18]; [@bib55]; [@bib47]), which changes the physical properties of cellular membranes and supports the dynamic assembly of nanoscale membrane domains ([@bib63]).

The best known case is β~2~AR, which is a prototype of cholesterol-interacting GPCRs. β~2~AR belongs to the family of class A GPCRs. GPCRs belonging to this class show a high structural similarity and functional diversity. The literature reporting on the specific functional role of cholesterol and other lipids is extensive ([@bib59]; [@bib19]). It has been experimentally shown that cholesterol affects the conformation ([@bib47]; [@bib6]) and function ([@bib18]; [@bib55]; [@bib59]; [@bib6]; [@bib25]) of many GPCRs. Based on X-ray crystal structures cholesterol has specific contacts with β~2~AR ([@bib7]; [@bib20]), suggesting that β~2~AR has binding sites for cholesterol. Spectroscopic ([@bib16]) and MD simulation ([@bib5]; [@bib58]; [@bib38]) studies have reported direct interactions between cholesterol and GPCRs, including β~2~AR. Experimental data show that cholesterol binding to β~2~AR changes its structural properties ([@bib20]; [@bib67]). Cholesterol is also necessary in crystallizing β~2~AR ([@bib7]; [@bib20]), and cholesterol and its analogue cholesteryl hemisuccinate (CHS) have been exhibited to improve β~2~AR stability ([@bib67]; [@bib42]). Since the structure and function of GPCRs are closely related, cholesterol binding specifically to β~2~AR is also expected to change the functional properties of the receptor. Indeed experimental studies indicate that cholesterol has a functional role in β~2~AR ([@bib55]; [@bib57]; [@bib65]). Further, inhibition of β~2~AR-associated signaling has been observed with increasing membrane cholesterol content ([@bib57]). However, as with GPCRs in general, the atomic-scale mechanism cholesterol uses to regulate β~2~AR is not known. Does cholesterol modulate β~2~AR activity through membrane-mediated effects by altering the physical properties of the membrane? Alternatively if regulation takes place through specific direct interactions, then what is the atom-scale mechanism?
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Results {#s2}
=======

Cholesterol restricts β~2~AR conformation {#s2-1}
-----------------------------------------

We first studied the impact of cholesterol on the conformational distribution of β~2~AR by systematically increasing the cholesterol concentration from 0 to 40 mol% in a DOPC (1,2-dioleoyl-*sn*-glycero-3-phosphocholine) bilayer. Crystallographic studies and previous biophysical and biochemical studies have shown that helices 5--6 (H5-H6) ([Figure 1A](#fig1){ref-type="fig"}) constitute a highly dynamic region of β~2~AR ([@bib30]). Upon activation, the most dramatic conformational change, which is conserved among many GPCRs, is a 7--14 Å outward movement of the intracellular end of H6 from the heptahelical core of the receptor ([@bib44]; [@bib30]). The large rearrangement in the G protein-coupling interface is accompanied by a comparatively subtle change in the ligand-binding pocket. In a conformational change from the inactive to the active state β~2~AR, H5 (around S207^5.46^) has been found to move inward by 2 Å to establish an optimal interaction between the agonist and the two anchor sites (D113^3.32^/N312^7.39^ and S203^5.42^/S204^5.43^/S207^5.46^) on the receptor ([@bib30]).10.7554/eLife.18432.004Figure 1.Conformational dynamics of β~2~AR.(**A**) The distances between the Cα atoms of D113^3.32^--S207^5.46^ (distance defined as L~L~) and R131^3.50^--E268^6.30^ (L~G~) pairs used to measure the fluctuations at the ligand and G-protein binding sites, respectively. (**B--C**) The conformational distributions of β~2~AR in membranes with 0 and 10 mol% cholesterol (Chol) as a function of L~L~ and L~G~. The gray dotted lines represent the corresponding L~L~ and L~G~ values in the inactive crystal structure of β~2~AR ([@bib20]). The cartoon diagram shows the fluctuations of L~L~ and L~G~ at the ligand and G-protein binding sites of the receptor, respectively. (**D--E**) The time evolution of L~L~ (light red) and L~G~ (light blue) in systems with 0 and 10 mol% cholesterol. Corresponding 50-point running averages are shown in dark colors. (**F**) Standard deviation for the distribution of the distance between the intracellular (IC) (or extracellular (EC)) end of H5 and its average position, and its dependence on whether the given end of H5 is in contact with cholesterol or not; similarly for H6.**DOI:** [http://dx.doi.org/10.7554/eLife.18432.004](10.7554/eLife.18432.004)10.7554/eLife.18432.005Figure 1---figure supplement 1.Conformational distributions of β~2~AR in lipid bilayers with various cholesterol (Chol) concentrations.In panels (**A--F**) the distributions are plotted as a function of L~L~ (distance between the Cα atoms of D113^3.32^ and S207^5.46^) at the ligand binding site and L~G~ (distance between the Cα atoms of R131^3.50^ and E268^6.30^) at the G protein-binding site. (**A--E**) Starting from situations where no cholesterol molecules were initially bound to β~2~AR, distributions are plotted over all independent trajectories of a given system, where the equilibration time (the first 100 ns) was discarded from the analysis. (**F**) β~2~AR conformational distribution in control simulations, where cholesterol molecules were initially bound at the eight interaction sites of β~2~AR predicted by our simulations, but no further cholesterol was in the membrane (total (average) cholesterol concentration 1.9 mol%). Here, there is reason to keep in mind the rapid migration of cholesterols away from the receptor surface when the cholesterol concentration is low (see main text and [Figure 5](#fig5){ref-type="fig"}), implying that panel (**F**) corresponds to cholesterol-rich conditions in the vicinity of the receptor at very short times but to cholesterol-poor conditions at long times.**DOI:** [http://dx.doi.org/10.7554/eLife.18432.005](10.7554/eLife.18432.005)

In the present work where we started from the inactive structure of β~2~AR ([@bib45]), we calculated the distance between the Cα atoms of D113^3.32^ and S207^5.46^ (referred to as L~L~) to measure the displacement of H5 in the ligand-binding site, and the distance between the Cα atoms of R131^3.50^ and E268^6.30^ (referred to as L~G~) to determine the displacement of H6 in the G protein-binding site ([Figure 1A](#fig1){ref-type="fig"}); the position of H3 does not change noticeably (RMSD \< 0.8 Å) during the simulations. These two parameters (L~L~ and L~G~) have been used in many previous studies to monitor changes in β~2~AR conformation ([@bib44]; [@bib30]; [@bib50]; [@bib12]; [@bib53]; [@bib13]; [@bib45]), thus here we discuss the conformational distribution of the receptor as a function of L~L~ and L~G~ ([Figure 1B,C](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). In the inactive crystal structure, the L~L~ and L~G~ values are 12.07 and 11 Å, respectively ([@bib20]).

In a cholesterol-free DOPC bilayer, we find β~2~AR to adopt a wide range of conformations with L~L~ varying between \~11.5--17.5 Å and L~G~ ranging between \~7.5--12.5 Å ([Figure 1B](#fig1){ref-type="fig"}). The receptor populates two major conformational states. One of them has a relatively open G protein site (L~G~ being 10--12 Å) and a smaller ligand-binding site (L~L~ \~ 13 ± 1 Å). The other conformation is characterized by a shift of \~3--4 Å from the intracellular end of H6 towards the receptor core that blocks the G protein interface (L~G~ \~ 8.5 Å). At the same time, the ligand-binding pocket expands as the extracellular part of H5 moves \~ 4--5 Å away from H3 (L~L~now \~16 ± 1 Å). This conformation represents an alternative inactive structure of the receptor, as both changes occur in the opposite direction compared to the case of agonist binding ([@bib30]); we do not observe any transition to the active state of β~2~AR. [Figure 1D](#fig1){ref-type="fig"} shows the receptor oscillating between the different inactive conformations during 2.5 µs. The closing of the intracellular G protein-binding surface is found to correlate with the opening of the extracellular ligand-binding pocket, and vice-versa ([Figure 1D](#fig1){ref-type="fig"}). The conformational correlation between the two distal sites supports the view of allosteric regulation in GPCRs ([@bib30]; [@bib53]).

In the presence of cholesterol, the picture changes quite dramatically. With a cholesterol concentration of 10 mol%, the conformational flexibility of β~2~AR reduces significantly ([Figure 1C](#fig1){ref-type="fig"}). The receptor stays predominantly in one conformation and no further opening of the ligand-binding site or the opening/closing of the G protein-binding site is observed, unlike in a cholesterol-free membrane. As shown in [Figure 1E](#fig1){ref-type="fig"}, L~L~ and L~G~ fluctuate around \~13 and\~9.5 Å, respectively. The slowing down of the movements of H5 and H6 correlates with the observed high-density spots of cholesterol at these helices (IC2 and EC1 in [Figure 2](#fig2){ref-type="fig"} discussed in detail below). To further quantify this, [Figure 1F](#fig1){ref-type="fig"} depicts the standard deviation for the fluctuations of the intracellular and extracellular ends of H5 and H6, when these ends are bound or unbound to cholesterol. The data show that the deviations of these helices from their respective average positions are much smaller when they are bound to cholesterol. The effect is particularly strong for the extracellular end of H5 at the ligand-binding site and for the intracellular end of H6 at the G protein-binding site.10.7554/eLife.18432.006Figure 2.Cholesterol interaction sites on β~2~AR.(**A--B**) 2D number densities of cholesterol (Chol) around β~2~AR. The data are averaged over all independent trajectories for a given cholesterol concentration ([Table 1](#tbl1){ref-type="table"}) and normalized with respect to the maximum density for that particular cholesterol concentration. The intracellular (IC) and extracellular (EC) bilayer leaflets are depicted separately. The major cholesterol interaction sites (IC1, IC2 and EC1) are marked in the density plots. The IC and EC sides of the transmembrane regions (H1--H7) of β~2~AR are shown in gray scale (the darker the color, the higher is the number density) and numbered accordingly. (**C--D**) Cartoon representation of three main cholesterol interaction sites in β~2~AR. IC1 (H1--H4) and IC2 (H5--H6) are located on the intracellular side, and EC1 comprised of two closely placed cholesterols between H5-H6 and H6-ECL3-H7 is located on the extracellular side of β~2~AR.**DOI:** [http://dx.doi.org/10.7554/eLife.18432.006](10.7554/eLife.18432.006)10.7554/eLife.18432.007Figure 2---figure supplement 1.Residues of β~2~AR involved in cholesterol binding, and cholesterol interaction sites on β~2~AR.Panels (**A--B**) (top): Cholesterol occupancy time per residue of β~2~AR described in terms of the normalized time fraction, where a value of one stands for a contact throughout the simulation trajectory and zero means no contact. Results are given for (**A**) 10 and (**B**) 40 mol% of cholesterol. The residues of β~2~AR are defined to be in contact with cholesterol when any non-hydrogen atom of the residue is within ≤0.5 nm of any heavy atom of cholesterol. The data show that there are several hot spots (blue) as cholesterol binding sites. These plots were averaged from all independent simulations for a given cholesterol concentration, where the equilibration time (the first 100 ns of the simulation) was disregarded from the analysis. Panels (**C**) (bottom): Interaction sites as obtained from our simulations, are shown from two perspectives around the protein. EC and IC stand for extracellular and intracellular, respectively. Interaction sites at the intracellular (IC) side: IC1 (dark green) between helices (**H**) 1--4, IC2 (red) between H5 and H6, IC3 (magenta) between H3 and H5, and IC4 (orange) between H1 and H8. Interaction sites at the extracellular (EC) side: EC1 comprised of two closely placed cholesterol molecules between H5 and H6 (cyan) and in space surrounded by H6-ECL3-H7 (green), EC2 (purple) between H3 and H4, and EC3 (blue) between H1-H2-ECL1 (where ECL stands for the extracellular loop).**DOI:** [http://dx.doi.org/10.7554/eLife.18432.007](10.7554/eLife.18432.007)10.7554/eLife.18432.008Figure 2---figure supplement 2.Sequence alignment of β~2~AR orthologues around the cholesterol-binding site IC1.The residues that play a major role (contact fraction ≥ 0.4, where one stands for maximum contact and zero for no contact) in cholesterol binding are highlighted. Here for IC1, the residues in the cholesterol consensus motif are highlighted in red. Following sequence alignment, shown are the contact fraction per residue (tan bars) and its occurrence in the set of sequences (cyan bars) \[one stands for 100% and zero for no occurrence\]. The occurrence represents the extent a particular residue is conserved.**DOI:** [http://dx.doi.org/10.7554/eLife.18432.008](10.7554/eLife.18432.008)10.7554/eLife.18432.009Figure 2---figure supplement 3.Sequence alignment of β~2~AR orthologues around the cholesterol-binding site IC2.The residues that play a major role (contact fraction ≥ 0.4, where one stands for maximum contact and zero for no contact) in cholesterol binding are highlighted. Following sequence alignment, shown are the contact fraction per residue (tan bars) and its occurrence in the set of sequences (cyan bars) \[one stands for 100% and zero for no occurrence\]. The occurrence represents the extent a particular residue is conserved.**DOI:** [http://dx.doi.org/10.7554/eLife.18432.009](10.7554/eLife.18432.009)10.7554/eLife.18432.010Figure 2---figure supplement 4.Sequence alignment of β~2~AR orthologues around the cholesterol-binding site EC1.The residues that play a major role (contact fraction ≥ 0.4, where one stands for maximum contact and zero for no contact) in cholesterol binding are highlighted. Following sequence alignment, shown are the contact fraction per residue (tan bars) and its occurrence in the set of sequences (cyan bars) \[one stands for 100% and zero for no occurrence\]. The occurrence represents the extent a particular residue is conserved.**DOI:** [http://dx.doi.org/10.7554/eLife.18432.010](10.7554/eLife.18432.010)10.7554/eLife.18432.011Figure 2---figure supplement 5.Cholesterol density around the receptor at low cholesterol concentrations.Two-dimensional (2D) averaged and normalized number densities of cholesterol around β~2~AR shown at low cholesterol concentrations (2 and 5 mol%). The intracellular and extracellular leaflets are depicted separately. The intracellular and extracellular sides of the transmembrane regions of β~2~AR are shown in gray scale (the darker the color, the higher is the number density), and they are numbered accordingly to show the locations of the individual helices (H1--H7).**DOI:** [http://dx.doi.org/10.7554/eLife.18432.011](10.7554/eLife.18432.011)10.7554/eLife.18432.012Figure 2---figure supplement 6.Structure of cholesterol analogues and properties of sterol-containing bilayers.(**A**) The different cholesterol analogues used in the current study. (**B--D**) Average lipid chain order parameter S~CD~ of DOPC bilayers with different concentrations of cholesterol or cholesterol-analogues. (**E--G**) Average bilayer thickness in DOPC bilayers with different concentrations of cholesterol or cholesterol-analogues. Error bars for order parameter and thickness are less than 0.02 and 0.005 Å, respectively.**DOI:** [http://dx.doi.org/10.7554/eLife.18432.012](10.7554/eLife.18432.012)10.7554/eLife.18432.013Figure 2---figure supplement 7.Interactions of cholesterol and cholesterol-like molecules with β~2~AR.The average interaction energies for van der Waals (vdW) and electrostatic interactions are determined separately. Error bars are in the range of 0.1--1 kJ/mol. The lower panel represents the oxysterol-containing systems, where a fraction of cholesterol is replaced by 4β-OH-Chol and 27-OH-Chol, respectively, resulting in bilayers with 4 mol% oxysterol and 21 mol% cholesterol.**DOI:** [http://dx.doi.org/10.7554/eLife.18432.013](10.7554/eLife.18432.013)10.7554/eLife.18432.014Figure 2---figure supplement 8.Densities of sterols around β~2~AR.Normalized 2D average number densities around β~2~AR: (**A--B**) CHSA (the deprotonated form of cholesteryl hemisuccinate (CHS)); (**C--F**) CHS. Densities of sterols in mixed sterol-containing bilayers with other molecules: (**G--H**) 4β-hydroxy-Chol (4β-OH-Chol); (**K--L**) 27-hydroxy-Chol (27-OH-Chol). The densities of 4β-OH-Chol and 27-OH-Chol are shown separately: (**I--J**) 4β-OH-Chol; (**M--N**) 27-OH-Chol. For descriptions of models, see [Table 1](#tbl1){ref-type="table"}. For each system, the intracellular and extracellular bilayer leaflets are depicted separately. The intracellular and extracellular sides of β~2~AR transmembrane regions (H1--H7) are shown in gray scale (the darker the color, the higher the number density) and numbered accordingly.**DOI:** [http://dx.doi.org/10.7554/eLife.18432.014](10.7554/eLife.18432.014)10.7554/eLife.18432.015Figure 2---figure supplement 9.Conformational distributions of β~2~AR in lipid bilayers with different cholesterol analogues.(**A--B**) Oxysterol-containing systems having 4 mol% of oxysterol (27-OH-Chol or 4β-OH-Chol) and 21% cholesterol. (**C--D**) DOPC bilayer with 10 mol% and 40 mol% of CHS. Conformational distributions are calculated over all independent trajectories of a given system, where the equilibration time (100 ns) is disregarded from the analysis. The CαD113^3.32^--CαS207^5.46^ (defined as L~L~) and CαR131^3.50^--CαE268^6.30^ (L~G~) distances represent the fluctuations in the ligand and the G protein-binding sites, respectively.**DOI:** [http://dx.doi.org/10.7554/eLife.18432.015](10.7554/eLife.18432.015)10.7554/eLife.18432.016Figure 2---figure supplement 10.IC1 interaction site.Specific cholesterol binding site in β~2~AR with the cholesterol consensus motif displayed with side chain positions of the conserved amino acid residues, as found in (**A**) the crystal structure (ref. 17) and (**B**) during our simulation. In the simulation snapshot, residues are colored according to their strength of interaction with cholesterol (red represents the weakest and blue represents the strongest interaction). (**C**) As to the time-dependent distance between H4 and its average position, as the H4 helix fluctuates around its average location, shown here are results for the standard deviation of the distance fluctuations. Data are given for cases, where IC1 is occupied (blue) or unoccupied (orange) by cholesterol.**DOI:** [http://dx.doi.org/10.7554/eLife.18432.016](10.7554/eLife.18432.016)

The restricted dynamics of β~2~AR is also observed at higher cholesterol concentrations (25 and 40 mol%; [Figure 1---figure supplement 1D,E](#fig1s1){ref-type="fig"}). In these cases, the receptor samples a similar conformational space as observed with 10 mol% cholesterol. At lower concentrations (2 and 5 mol%), the distribution of the receptor's conformation is much wider ([Figure 1---figure supplement 1A,B](#fig1s1){ref-type="fig"}). Particularly when the membrane contains a very small percentage of cholesterol (2 mol%), the range of conformations accessible to β~2~AR is almost comparable to that of a cholesterol-free membrane.

A broad conformational distribution ([Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}) is also observed in control simulations, where eight cholesterol molecules were initially placed at the cholesterol-binding sites of β~2~AR predicted by our simulations (see below), and this receptor-cholesterol complex was then embedded in a cholesterol-free membrane. Here ([Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}) the concentration of cholesterol in the annular region is therefore high in the beginning of the simulation, while it is zero elsewhere. Cholesterols dissociate from β~2~AR during the course of the simulation (discussed in detail below) and at long times the system corresponds to a dilute (cholesterol-poor) system, where the total average cholesterol concentration is low (1.9 mol%). One finds that as the data are averaged over the simulation period, the conformational behavior ([Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}) translates from cholesterol-rich ([Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}) to cholesterol-poor behavior ([Figure 1---figure supplement 1A,B](#fig1s1){ref-type="fig"}).

Further, we studied the effect of cholesterol on the active conformation of β~2~AR in its apo form in the absence of the G protein ([@bib60]). In the active state, the intracellular end of H6 is splayed outward from the helical bundle, providing room for the G protein ([Figure 3A](#fig3){ref-type="fig"}). We observe inward swinging of H6 towards H3 in the absence of cholesterol (which occurred in two out of three replica simulations). As shown in [Figure 3B,E](#fig3){ref-type="fig"}, the intracellular end of H6 spontaneously approaches H3 with L~G~ dropping from 18.97 Å in the starting active conformation to \~11.5 Å that is comparable to the crystallographically observed inactive conformation of β~2~AR (L~G~ \~ 11 Å) ([@bib20]). Such spontaneous deactivation of the receptor in the absence of the intracellular binding partner and cholesterol is in agreement with recent simulations ([@bib13]; [@bib48]) and experimental studies ([@bib61]). Meanwhile, with 40 mol% cholesterol, we observe that the active-like open conformation is stable during the simulations ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). As shown in [Figure 3C,E](#fig3){ref-type="fig"}, the L~G~ value remains stable around 16.5 Å and no deactivation is observed unlike in cholesterol-free systems. Interestingly, here again we found a high cholesterol density at the intracellular segments of H5-H6 (IC2 in [Figure 3C,D](#fig3){ref-type="fig"},F as discussed in detail below).10.7554/eLife.18432.017Figure 3.Effect of cholesterol on the active conformation of β~2~AR.Cytosolic view of β~2~AR (**A**) in the beginning of a simulation (active state) as well as in representative simulation snapshots in (**B**) a DOPC bilayer and (**C**) in the presence of 40 mol% cholesterol. The dotted line represents the distance between the Cα atoms of R131^3.50^--E268^6.30^ (defined as L~G~), used to measure the fluctuation at the G protein-binding site. (**D**) Simulation snapshot (in the presence of 40 mol% cholesterol) showing cholesterol binding at the interaction sites of β~2~AR. (**E**) The time evolution of L~G~ in systems with 0 (light red) and 40 mol% cholesterol (light blue). Corresponding 50-point running averages are shown in dark colors (red, blue). (**F**) 2D number densities of cholesterol around β~2~AR (cytosolic view). The individual transmembrane helixes of β~2~AR are numbered and shown in gray scale (as in [Figure 2A,B](#fig2){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.18432.017](10.7554/eLife.18432.017)10.7554/eLife.18432.018Figure 3---figure supplement 1.Conformational distribution of β~2~AR starting from the active state.The conformational distributions of β~2~AR in (left) a DOPC bilayer and (right) a DOPC bilayer with 40 mol% cholesterol (Chol) as a function of L~L~ and L~G~. The gray dotted lines represent the corresponding L~L~ and L~G~ values in the initial active crystal structure of β~2~AR. The distribution is averaged over the different replicas of each system.**DOI:** [http://dx.doi.org/10.7554/eLife.18432.018](10.7554/eLife.18432.018)

These results show that cholesterol restricts the intrinsic conformation dynamics of β~2~AR and governs changes between different conformational states, thereby modulating its function.

Specific binding of cholesterol {#s2-2}
-------------------------------

In all of the simulations ([Table 1](#tbl1){ref-type="table"}), cholesterol is observed to diffuse spontaneously to the receptor's surface. Time-averaged two-dimensional (2D) number density maps demonstrate that there are preferred cholesterol positions around β~2~AR ([Figure 2A,B](#fig2){ref-type="fig"}).

Localized cholesterol hot spots are often used as an indicator of potential cholesterol binding sites. We identify three such cholesterol interaction sites -- two on the intracellular side (IC1 and IC2) and one on the extracellular side (EC1) ([Figure 2](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1A,B](#fig2s1){ref-type="fig"}). Here we call them high-affinity sites since they reproducibly exhibit high cholesterol densities (normalized number density above 0.7) at different cholesterol concentrations ([Figure 2A,B](#fig2){ref-type="fig"}) and also have large lifetimes as the below discussion shows. IC1 is a shallow groove formed by the intracellular parts of transmembrane helices H1-H4 and coincides well with the location of cholesterol observed in the crystal structure of β~2~AR ([@bib7]; [@bib20]). In IC2 cholesterol penetrates deep into the cleft between H5 and H6 on the intracellular side. A high density of cholesterol is observed at IC2 not only in the inactive but also in the active β~2~AR conformation ([Figure 3C,D,F](#fig3){ref-type="fig"}), which suggests that this site is biologically important.

EC1 is comprised of two closely spaced cholesterol hot spots located in the extracellular part of H5-H6 and H6-ECL3-H7 (where ECL stands for the extracellular loop). The occupancy of two cholesterol molecules at EC1 is in good agreement with the crystal structure of the adenosine receptor A~2A~AR ([@bib41]), while IC2 is so far unidentified among the experimentally determined structures ([@bib16]). Notably, the cholesterol binding residues of the three interaction sites are conserved to a large degree among β~2~AR orthologues ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}, [Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}, [Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}), indicating that these sites have conserved during the evolution of the receptor. In addition, a few comparatively low-affinity cholesterol binding sites (IC3-4, EC2-3) with 10 and 40 mol% cholesterol are observed ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). When cholesterol concentration is lowered below 10 mol%, many of the interaction sites, particularly IC1 and EC1, are occupied by cholesterol at concentrations as low as 5 mol% ([Figure 2---figure supplement 5](#fig2s5){ref-type="fig"}). A few sites (IC2 and EC1) are visited, though transiently, by cholesterol even at 2 mol% ([Figure 2---figure supplement 5](#fig2s5){ref-type="fig"}).

In addition to the above-discussed cholesterol hot spots, we observed two sites with comparatively weak cholesterol occupancies (reproducible at both 10 and 40 mol% cholesterol concentrations): IC3 between H3 and H5, and IC4 between H1 and H8, both on the intracellular side ([Figure 2A,B](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). IC4 recaptures the predicted cholesterol position at the dimerization interface of β~2~AR found by X-ray crystallography ([@bib7]). Besides these, another site with a low cholesterol density was observed near the extracellular part of H3-H4 (EC2) in the 10 mol% cholesterol system, and a high-density site was observed on the extracellular side of H1-H2-EC1 (EC3) in the 40 mol% cholesterol system ([Figure 2A,B](#fig2){ref-type="fig"}).

Concluding, we find cholesterol to bind to β~2~AR in specific binding sites. These sites are in agreement with those found in the crystallographic structures of GPCRs ([@bib7]; [@bib20]; [@bib19]; [@bib64]; [@bib41]; [@bib16]).

Membrane-mediated interactions not the key {#s2-3}
------------------------------------------

Is it possible that the effects we observed on β~2~AR conformation could be due to cholesterol-induced changes in membrane properties, and the changes in β~2~AR would hence not be due to the specific direct binding of cholesterol in the hot spots? To unlock this issue, we study the conformational properties of β~2~AR in cholesterol-free membranes whose physical properties (thickness, order, diffusion) match those of membranes with a large concentration of cholesterol.

A.  *Effect of increased bilayer thickness.* We studied β~2~AR embedded in a bilayer composed of long-chain mono-unsaturated phosphatidylcholine (PC) lipids PC-20:0/22:1 c13 ([@bib31]). The thickness of this membrane is larger than the thickness of a DOPC bilayer with 40 mol% cholesterol, while its lipid chain order is comparable to a DOPC bilayer with 5% cholesterol ([Figure 4---figure supplement 1A,B](#fig4s1){ref-type="fig"}). [Figure 4A](#fig4){ref-type="fig"} depicts that the increased bilayer thickness is unable to restrict the conformational dynamics of β~2~AR. The receptor just adjusts itself to the hydrophobic mismatch by inducing bilayer thinning (4--8 Å) in its vicinity ([Figure 4B](#fig4){ref-type="fig"}).

B.  *Effect of increased bilayer order.* We then studied β~2~AR placed in a DOPC bilayer with 20 mol% pyrene, which is known to induce similar (ordering and condensing) effects as cholesterol ([@bib10]). [Figure 4D](#fig4){ref-type="fig"} highlights that pyrene does not show any preference for specific binding on the β~2~AR surface except for the slowed-down diffusion of pyrene near the receptor surface. β~2~AR exhibits a very broad conformational distribution, with L~L~ and L~G~ fluctuating between \~9--17.5 and \~7--13.5 Å, respectively ([Figure 4C](#fig4){ref-type="fig"}). This conformational behavior of the receptor is distinctly different from the one induced by ≥10 mol% cholesterol, although the order of the pyrene-containing bilayer is similar to a DOPC bilayer with 10 mol% of cholesterol ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}).

![Impact of membrane-mediated effects on the β~2~AR conformation.\
The conformational distribution of β~2~AR in bilayers composed of (**A**) long-chain PC-20:0/22:1 c13 lipids and (**C**) DOPC with 20 mol% pyrene (Pyrene20). (**B**) 3D-distribution of bilayer thickness in the thicker PC-20:0/22:1 c13 membrane. The receptor is shown as a purple cartoon. (**D**) 2D number density of pyrene around β~2~AR.\
**DOI:** [http://dx.doi.org/10.7554/eLife.18432.019](10.7554/eLife.18432.019)](elife-18432-fig4){#fig4}

Summarizing, the changes in physical membrane properties, similar to those induced by cholesterol, do not restrict the conformational dynamics of β~2~AR. We conclude that the cause of the observed changes in β~2~AR conformation and dynamics is the specific binding of cholesterol to β~2~AR.

Binding lifetime depends on cholesterol {#s2-4}
---------------------------------------

When cholesterol is specifically bound to β~2~AR, how stable is the binding? [Figure 5](#fig5){ref-type="fig"} depicts the time-correlation function of cholesterol binding in the three main binding sites (IC1, IC2, EC1) on β~2~AR and shows that at low cholesterol concentrations (2--5 mol%) the binding lifetime is short, of the order of 100 ns or less. However, at \~10 mol% there is a clear transition to longer lifetimes (see [Video 1](#media1){ref-type="other"} and [Video 2](#media2){ref-type="other"}) given that the lifetime of binding increases to the microsecond time scale for 10 and 40 mol% cholesterol.10.7554/eLife.18432.021Figure 5.Binding time of cholesterol.(**A--C**) Time-correlation function of cholesterol (Chol) at the three major interaction sites (IC1, IC2, EC1) on the β~2~AR surface. Initially cholesterol is bound to the site (distance ≤ 0.5 nm) and the correlation function describes the probability that cholesterol remains bound to the given site for increasing time. Data are shown for DOPC-cholesterol membranes with 2, 5, 10, and 40 mol% of cholesterol. (**D--E**) Schematic representation showing the transition from fast to slow exchange as cholesterol concentration increases from 2 to 40 mol%. Color code: β~2~AR (blue), DOPC (thin grey lines), cholesterol molecules bound to the interaction sites (purple), and other cholesterol molecules not bound to the receptor (yellow sticks).**DOI:** [http://dx.doi.org/10.7554/eLife.18432.021](10.7554/eLife.18432.021)10.7554/eLife.18432.022Figure 5---figure supplement 1.Interaction of cholesterol with β~2~AR.Time development for the distances of cholesterol molecules from the β~2~AR surface, where these cholesterol molecules were initially bound at the eight binding sites identified in this study (cholesterol-bound, see [Table 1](#tbl1){ref-type="table"}; [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Here, EC1-A and EC1-B stand for the two cholesterol molecules in the EC1 binding site. The rest of the membrane was initially cholesterol-free. Shown here are the data based on the three independent repeats.**DOI:** [http://dx.doi.org/10.7554/eLife.18432.022](10.7554/eLife.18432.022)Video 1.Spontaneous binding/unbinding of cholesterol at the three main cholesterol interaction sites of β~2~AR during a 2.5-μs simulation with 10 mol% of cholesterol.Cholesterols interacting at the cholesterol-binding sites are highlighted (yellow at IC1; green at IC2; and blue and red at EC1). Other cholesterols are shown in gray. For clarity, other lipids in a membrane are not shown.**DOI:** [http://dx.doi.org/10.7554/eLife.18432.023](10.7554/eLife.18432.023)10.7554/eLife.18432.023Video 2.Spontaneous binding/unbinding of cholesterol at the three main cholesterol interaction sites of β~2~AR during a 2.5-μs simulation with 40 mol% of cholesterol.Cholesterols interacting at the cholesterol-binding interaction sites are highlighted (yellow and green at IC1; red, blue and orange at IC2; and pink, purple and cyan at EC1). Other cholesterols are shown in gray. For clarity, other lipids in a membrane are not shown.**DOI:** [http://dx.doi.org/10.7554/eLife.18432.024](10.7554/eLife.18432.024)10.7554/eLife.18432.024

In three control simulations where cholesterols were initially bound at the eight cholesterol-binding sites identified in our simulations and no further cholesterol was in the bilayer ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), cholesterols underwent rapid unbinding from the majority of the binding sites in a timescale of tens to hundreds of nanoseconds ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), similarly to the short binding lifetime observed for cholesterol-poor systems (2 mol%, [Figure 5](#fig5){ref-type="fig"}). However, at a few sites cholesterol stayed for the entire simulation time (IC1 and IC2 in two out of three simulations) or dissociated in the μs timescale (IC3 and EC3 in one simulation).

The results show that the lifetime of cholesterol is of the order of microseconds in the high-affinity binding sites, where the lifetime at large cholesterol concentrations is largely independent of cholesterol concentration.

Cholesterol analogues interact with β~2~AR {#s2-5}
------------------------------------------

We next explore how cholesterol analogues, in comparison to cholesterol, interact with β~2~AR. We focus on four different analogues ([Table 1](#tbl1){ref-type="table"}): (i-ii) cholesteryl hemisuccinate (CHS) and its deprotonated form (CHSA), and (iii-iv) two oxysterols, 4β-hydroxycholesterol (4β-OH-Chol) and 27-hydroxycholesterol (27-OH-Chol), oxidized at the cholesterol ring and tail, respectively ([Figure 2---figure supplement 6A](#fig2s6){ref-type="fig"}). As compared to cholesterol, CHS is a more water-soluble cholesterol ester and is widely used in structural biology and biophysical studies as a cholesterol analogue ([@bib67]; [@bib42]). Oxysterols, on the other hand, are derivatives of cholesterol with additional oxygen-containing substitutions at different positions of cholesterol ([@bib52]; [@bib33]; [@bib49]). Due to the structural similarities with cholesterol, these analogues mimic cholesterol as to the effects on membrane properties (e.g., increasing bilayer order and thickness), although to different extents ([Figure 2---figure supplement 6](#fig2s6){ref-type="fig"}) ([@bib33], [@bib32]).

CHSA is found to interact strongly with β~2~AR due to the enhanced electrostatic coupling resulting from its negatively charged head-group ([Figure 2---figure supplement 7](#fig2s7){ref-type="fig"}), however it favors to reside around the receptor at locations different from those of cholesterol ([Figure 2---figure supplement 8A,B](#fig2s8){ref-type="fig"}). Meanwhile, CHS closely mimics the behavior of cholesterol ([Figure 2---figure supplement 7](#fig2s7){ref-type="fig"}). Among the three major cholesterol interaction sites observed in our simulations, we find a very high CHS density at IC2 ([Figure 2---figure supplement 8C--F](#fig2s8){ref-type="fig"}). High occupancy of CHS is also observed near IC1 (at 40 mol% CHS concentration) but not at all at EC1. Occupancy of CHS at IC1 is consistent with the crystal structure of β~1~AR ([@bib64]).

4β-OH-Chol interacts only weakly with β~2~AR ([Figure 2---figure supplement 7](#fig2s7){ref-type="fig"}). Almost all of the interaction sites on the receptor surface are occupied by cholesterol rather than 4β-OH-Chol ([Figure 2---figure supplement 8G--J](#fig2s8){ref-type="fig"}). As a result, the average density maps, showing the lateral arrangement of these sterols around β~2~AR, are similar to those of 10 and 40 mol% cholesterol systems ([Figure 2A](#fig2){ref-type="fig"}), and reproducible. Unlike 4β-OH-Chol, 27-OH-Chol prefers to interact with the receptor directly ([Figure 2---figure supplement 7](#fig2s7){ref-type="fig"}). For the IC1 site, 27-OH-Chol competes, though weakly, with cholesterol, while at EC1 and IC3, 27-OH-Chol exhibits preference over cholesterol ([Figure 2---figure supplement 8K--N](#fig2s8){ref-type="fig"}).

Altogether, our results show that also other cholesterol-like molecules interact with β~2~AR and may occupy the same binding sites on the receptor surface as cholesterol. However, the effects of cholesterol-analogues on β~2~AR are weaker compared to those induced by cholesterol ([Figure 2---figure supplement 9](#fig2s9){ref-type="fig"}). All the cholesterol analogues studied here have a rigid ring structure, yet their slightly different chemical compositions influence their occupancy as well as the strength of binding to the cholesterol-binding sites ([Table 2](#tbl2){ref-type="table"}). This is assessed here in terms of the van der Waals energy, which as a short-range interaction reflects how strongly two molecules are in contact and therefore serves as an appropriate measure for the gravity of lipid-protein binding in the binding site.10.7554/eLife.18432.025Table 2.Interactions^\*^ of sterols at the three high-affinity cholesterol-binding sites.**DOI:** [http://dx.doi.org/10.7554/eLife.18432.025](10.7554/eLife.18432.025)Cholesterol/Cholesterol analogue**High-affinity cholesterol interaction sitesIC1IC2EC1**vdW interaction energy (kJ/mol)No. of contactsvdW interaction energy (kJ/mol)No. of contactsvdW interaction energy (kJ/mol)No. of contactsCholesterol^†^−138.04 ± 0.20141.02 ± 0.22−95.06 ± 0.1290.65 ± 0.16−129.51 ± 0.29104.38 ± 0.28CHS−29.63 ± 0.1428.78 ± 0.16−98.75 ± 0.1196.30 ± 0.16\--27-OH-Chol−32.17 ± 0.3034.95 ± 0.33−22.69 ± 0.2328.41 ± 0.28−132.85 ± 0.27120.20 ± 0.304β-OH-Chol\-\-\--−41.80 ± 0.4833.41 ± 0.42[^5][^6]

The results in [Table 2](#tbl2){ref-type="table"} show that among the three major interaction sites, the binding of CHS at IC1 is much weaker than that of cholesterol. At IC2 the strength of interaction of CHS and cholesterol is comparable. Meanwhile, the extracellular EC1 site remains unoccupied by CHS indicating the binding energy to be low. As to the two oxysterols, 4β-OH-Chol interacts with β~2~AR only at EC1 and the interaction is weak, while 27-OH-Chol binds at EC1 as tightly as cholesterol, but its interaction at the two other binding sites (IC1 and IC2) is much weaker than in the case of cholesterol. Concluding, CHS interacts at IC2 as strongly as cholesterol but its interactions at IC1 and EC1 are negligible compared to those of cholesterol. The oxysterol 27-OH-Chol interacts at EC1 as strongly as cholesterol but its interactions at IC1 and IC2 are negligible compared to those of cholesterol. The oxysterol 4β-OH-Chol does not interact with β~2~AR to a significant degree.

These data can be considered in the context of molecular structures. In CHS, the difference compared to cholesterol is the additional chain bridged to the cholesterol structure via an ester bond ([Figure 2---figure supplement 6A](#fig2s6){ref-type="fig"}). This additional chain does not interfere binding at IC2, but it does alter the binding at IC1 and EC1. In 27-OH-Chol, the oxidation has taken place in the short acyl chain that is the terminal subunit of the molecule. This does not interfere the binding at EC1 but does alter the binding at IC1 and IC2. Finally, in 4β-OH-Chol, the oxidation has occurred in the rigid steroid moiety, making the α-side of the molecule rougher. In cholesterol, the α-side is exceptionally flat. Given this change in surface roughness, and the importance of the surface-surface contact in lipid-β~2~AR binding in the binding site, it is quite obvious why this oxysterol does not bind to any of the cholesterol binding sites (IC1, IC2, EC1).

The results support the view that the restriction of β~2~AR dynamics arises from specific lipid binding to the receptor binding sites: the tighter the binding, the more is the receptor dynamics suppressed, and cholesterol induces the strongest effect.

Discussion {#s3}
==========

Our results show that cholesterol has a preference to bind to β~2~AR at specific locations on its surface. We identified three high-affinity cholesterol interaction sites in β~2~AR ([Figure 2C,D](#fig2){ref-type="fig"}): IC1 (at the cleft of H1-H4 on the intracellular side), IC2 (H5-H6 on the intracellular side), and EC1 (the H5-H6-ECL3-H7 region on the extracellular side). IC1 and EC1 are in agreement with the locations of cholesterol found in GPCR crystal structures ([@bib7]; [@bib20]; [@bib41]). IC1 contains a cholesterol consensus motif that predicts cholesterol binding for 44% of human class A receptors ([@bib20]). Moreover, these binding sites appear to be evolutionarily conserved in β~2~AR, which suggests their possible allosteric role in receptor function. A recent simulation study reported a correlation between cholesterol occupancy at IC1 and β~2~AR dimerization ([@bib58]). However, not much is known about the functional relevance of cholesterol binding to the other sites of β~2~AR.

The present work for the inactive conformation of β~2~AR shows that cholesterol binding at IC2 and EC1 ([Figure 2C,D](#fig2){ref-type="fig"}) strongly influences the conformational dynamics of β~2~AR ([Figure 1](#fig1){ref-type="fig"}). In a cholesterol-free membrane the receptor samples multiple conformational states ([Figure 1B](#fig1){ref-type="fig"}) accounting for the high basal activity of β~2~AR ([@bib44]; [@bib30]). Our results show that the presence of cholesterol in high densities around H5-H6-H7 impedes the dynamic nature of the receptor. In cholesterol-containing (≥10 mol% cholesterol) membranes ([Figure 1C](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1D,E](#fig1s1){ref-type="fig"}), the overall structural flexibility of the receptor is significantly reduced to one predominant conformation. We observed that in the presence of strongly bound cholesterol, H5 and H6 undergo much smaller displacements from their average positions as compared to the situation without cholesterol ([Figure 1F](#fig1){ref-type="fig"}). Cholesterol analogues that occupy the same interaction sites also restrict the β~2~AR conformation ([Figure 2---figure supplement 9](#fig2s9){ref-type="fig"}), although their effects are weaker compared to those of cholesterol. Cholesterol or cholesterol-like molecules bound at these inter-helical clefts can thus confine the movement of the respective helices to a substantial degree, thus dampening the overall conformational dynamics of the receptor. At IC2 of inactive β~2~AR, cholesterol pushes the intracellular end of H6 more towards the core of the helical bundle and prevents the outward movement of H6 required for G protein binding. The restriction of H6 movement by cholesterol is a potentially important allosteric effect, which can be used to modulate the receptor activity.

Interestingly, our study on the active-state β~2~AR also exhibits a high cholesterol density at IC2 ([Figure 3D,F](#fig3){ref-type="fig"}). Here cholesterol bound at IC2 acts as a spacer between H5-H6 and restricts the movement of H6, thereby stabilizing the open active-like conformation of the receptor ([Figure 3D](#fig3){ref-type="fig"}), while in the absence of cholesterol the receptor is more prone to undergoing spontaneous deactivation ([Figure 3E](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). This result supports the postulate that cholesterol restricts the conformational dynamics of the receptor by binding at specific interaction sites and governs changes between different receptor states, therefore modulating its function. Moreover, cholesterol binding at IC2 in both inactive and active states of β~2~AR as found in our simulations highlights the biological relevance of this interaction site in allosteric regulation of the receptor conformation.

The highly conserved IC1 site shows no major influence on the mobility of H5-H6. On the other hand, IC1 exerts a stabilizing effect on H4 ([Figure 2---figure supplement 10](#fig2s10){ref-type="fig"}), in agreement with experiments ([@bib20]). As H4 is one of the weakest points of the β~2~AR fold, its decreased mobility may account for the enhanced stability of the receptor.

Cholesterol modulates the physical properties of membranes by increasing the bilayer thickness and order, and slowing down the dynamics. These general membrane effects can also influence the dynamic nature of a membrane protein ([@bib46]). However, here we found that membrane-mediated interactions do not affect β~2~AR conformation to a significant degree ([Figure 4](#fig4){ref-type="fig"}).

GPCRs are signaling machines that function by toggling between multiple conformers ([@bib37]). The dynamic nature of GPCRs has made their crystallization process extremely challenging ([@bib30]). Besides techniques like protein engineering and use of detergents to increase the intrinsic stability of the receptor ([@bib42]), cholesterol/CHS has emerged as a necessary component for crystallization of many GPCRs, including β~2~AR ([@bib7]; [@bib20]; [@bib67]; [@bib42]). Our work shows that in the presence of more than \~10 mol% cholesterol, inactive β~2~AR partly loses conformational variability and populates just one major conformation. Achieving conformational homogeneity is the key to crystallize membrane proteins ([@bib42]). In agreement with our results, a recent experimental study showed that CHS impacts the conformational dynamics of a GPCR leading to a restricted conformational space ([@bib6]). Earlier it was experimentally reported that cholesterol induces a more compact conformational state of the oxytocin receptor ([@bib47]). Our results are also in agreement with a recent dynamic single-molecule force spectroscopic study, which showed that CHS strengthens interactions that stabilize the structural segments in β~2~AR and thereby considerably increase the kinetic, energetic, as well as the mechanical stability of the receptor ([@bib67]). In addition, the function of adrenergic receptors is known to be modulated by cholesterol: cholesterol depletion enhances β~2~AR-associated signaling, while increased cholesterol content inhibits signaling ([@bib55]; [@bib57]).

To our knowledge, the results presented in this work provide the first atomic-scale picture of how lipids can govern the conformation of membrane receptors through direct lipid-protein interactions in specific lipid binding sites, and hence dictate the state of a receptor. The receptor-cholesterol interactions, such as those observed in our simulations for β~2~AR, can conceivably govern the signaling of many GPCRs in the given protein family.

Materials and methods {#s4}
=====================

We performed all-atom molecular dynamics simulations of β~2~AR embedded in lipid bilayers with various lipid compositions ([Table 1](#tbl1){ref-type="table"}) using the GROMACS 4.6.x software package.

Force field parameters {#s4-1}
----------------------

All simulations were performed using the GROMACS 4.6.x package ([@bib3]; [@bib22]). The all-atom OPLS-AA (optimized potentials for liquid simulations) force field was used to parameterize the protein, ions, and pyrene ([@bib28]; [@bib29]). Force field parameters for cholesterol, cholesteryl hemisuccinate, and oxysterols were taken from previously published papers ([@bib45]; [@bib33], [@bib32], [@bib36]). For the studied phosphatidylcholines (DOPC and PC-20:0/22:1 c13), we used new torsional and Lennard-Jones parameters derived for saturated ([@bib43]) and unsaturated hydrocarbons ([@bib34], [@bib35]) and the torsional potential developed for the glycerol backbone and the phosphatidylcholine head group ([@bib43]). The TIP3P model, which is compatible with the OPLS parameterization, was used for water molecules ([@bib27]).

Simulation protocols {#s4-2}
--------------------

All simulations of the systems considered in this work ([Table 1](#tbl1){ref-type="table"}) were performed under the isobaric-isothermal (NpT) ensemble. A time step of 2 fs was used for integrating the equations of motion. Periodic boundary conditions were applied in all three directions of the system. The temperature of the system was maintained at 310 K by employing the v-rescale (stochastic velocity rescaling) thermostat ([@bib4]) with a time constant of 0.1 ps. The temperatures of the receptor, lipids, and solvent molecules were controlled independently. The pressure of the system (1 bar) was maintained semi-isotropically using the Parrinello--Rahman barostat ([@bib56]) with a 1 ps time constant. The LINCS algorithm was applied to preserve hydrogen covalent bond lengths ([@bib21]). Lennard-Jones interactions were cutoff at 1.0 nm. The particle mesh Ewald (PME) method ([@bib14]) was employed for long-range electrostatic interactions using a real space cutoff of 1.0 nm, β-spline interpolation (order of 6), and a direct sum tolerance of 10^−6^.

Protein structure {#s4-3}
-----------------

The initial coordinates of β~2~AR were taken from our recently published work ([@bib45]), in which the structural modifications made for crystallization of the inactive β~2~AR structure \[PDB id: 3D4S\] ([@bib20]) were reverted back to its original sequence. This inactive crystal structure of β~2~AR bound to the partially inverse agonist timolol was heavily engineered to facilitate crystallization ([@bib20]). We reverted all the structural modifications from the experimentally determined structure, i.e., we removed mutations (E122^3.41^W on the transmembrane helix H3 and the N187^5.26^E mutation on the extracellular loop 2), removed the T4-lysozyme attached between the transmembrane helices 5 and 6, and replaced it with the missing intracellular loop 3. We did not attempt to model the unresolved N-terminal (32 residues) and C-terminal (71 residues) parts. The details of the procedure used to prepare the receptor model for our simulations are described elsewhere ([@bib45]). In the present work, we considered the apo-receptor (without a ligand), as we were interested in the intrinsic dynamics of β~2~AR.

For simulations with the active-state β~2~AR conformation, the starting structure was taken from the crystal structure of the receptor bound to an agonist and a Gs protein ([@bib60]). Here again we considered the apo-form of the receptor without the ligand and the G protein. Additionally, we removed the lysozyme and modeled the missing loop regions (A176-H178 and F240-F264), but the mutations were kept as such.

System setup {#s4-4}
------------

We simulated β~2~AR embedded in a number of lipid bilayers ([Table 1](#tbl1){ref-type="table"}) with varying lipid composition. The lipid contents used in the studies were as follows:

-   DOPC bilayers with different cholesterol (Chol) concentrations: 0, 2, 5, 10, 25, and 40 mol%.

-   DOPC bilayers with a cholesterol analogue cholesteryl hemisuccinate (CHS; 10 and 40 mol%) or its deprotonated form CHSA (10 and 40 mol%). CHS is known to enhance the stability of GPCRs. It is frequently used for GPCR characterization ([@bib67]; [@bib66]).

-   DOPC bilayers mixed with several sterols: 21 mol% cholesterol and 4 mol% oxidized sterol (4β-hydroxy-cholesterol (4β-OH-Chol) or 27-hydroxy-cholesterol (27-OH-Chol)). Oxysterols used in this study are among the most common oxysterols found in human serum ([@bib52]; [@bib33]).

-   A single-component bilayer composed of the long-tail monounsaturated phospholipid PC-20:0/22:1 c13.

-   DOPC bilayers with 20 mol% pyrene.

The lipid bilayers (without β~2~AR) were constructed using in-house scripts, and they were subsequently solvated with water. These lipid bilayers were then equilibrated for 100--200 ns.

Next, β~2~AR was placed into the above-mentioned pre-equilibrated bilayers in such a manner that the lipid arrangement around the receptor was completely random and that there was no cholesterol or cholesterol analogue initially bound to β~2~AR. For incorporating the receptor into a pre-equilibrated lipid bilayer, we followed our recently published method, where the receptor was pushed into a lipid membrane from its side by applying a high lateral pressure on the system ([@bib26]).

Each system contained one β~2~AR and 256--512 lipids. Each of the systems was explicitly solvated by water. In all cases, counterions (8 Cl^--^ ions for β~2~AR, and additional Na^+^ counter ions for bilayers containing the anionic CHSA) were added to maintain electroneutrality of the systems. NaCl salt was added to achieve the physiological salt concentration of 150 mM. Subsequently each system was energy minimized and then equilibrated in two stages with position restraints first on protein heavy atoms and then on the backbone. Following equilibration (100 ns), all restraints were released and the equilibrated systems were subjected to microsecond length (1--2.5 μs) production simulations. Multiple independent simulations were performed for each lipid composition, either by starting from a different lipid arrangement around β~2~AR (for systems with no sterols initially bound to the receptor) or starting with different initial velocities (for systems with sterols initially bound to the receptor).

Additional simulations were performed where cholesterol or its analogues were initially attached to certain locations on the surface of the receptor, and this receptor-lipid complex was then embedded to a cholesterol-free DOPC bilayer. Here we performed two sets of control simulations. In one set of simulations, two cholesterol or CHS (neutral or anionic) molecules were bound at the cleft formed by the intracellular side of the transmembrane helices H1-4 as predicted from the crystal structure ([@bib20]). In another set of control simulations, cholesterol molecules were initially bound at the eight interaction sites of β~2~AR predicted by our simulations (see discussion in the main article). The simulation conditions (as to counterions and salt, release of restrains, simulation times, etc.) were as described above.

The systems investigated in this study are summarized in [Table 1](#tbl1){ref-type="table"}. The total simulation time for the atomistic systems studied in this work covers a period of more than 100 μs.

Analysis of helix deviation {#s4-5}
---------------------------

For calculation of deviations of helix ends, we first calculated their time series of X, Y, and Z coordinates. The coordinates were then divided into two groups based on whether the upper and lower halves of the helixes (backbone atoms) were in contact ( ≤ 0.5 nm) with cholesterol (heavy atom) or not. Separately in each group, the distance from the average point of the group at each time frame (say *i*^th^ frame) was calculated by:$$d_{i}^{2} = (x_{i} - x_{g})^{2} + (y_{i} - y_{g})^{2} + \ \left( {z_{i} - z_{g\ }} \right)^{2},$$

where $x_{i}$, $y_{i}$, $z_{i}$ were the coordinates of the *i*^th^ frame, and $x_{g}$, $y_{g}$, $z_{g}$ were the average values. The standard deviation of each group was then calculated by:$$\sigma = \ \sqrt{\frac{1}{N_{g}}\sum\limits_{i = 1}^{N_{g}}d_{i}^{2}}$$

The average standard deviation of different simulations was calculated as a weighted average depending on the number of frames (*N~g~*) of the group in each simulation.

Two-dimensional (2D) number density map {#s4-6}
---------------------------------------

The 2D number density maps were calculated using the g_densmap tool of GROMACS. The two bilayer leaflets were calculated separately. The output was then processed (using an in-house script) to normalize the maximum number density to one. We calculated the 2D number densities of cholesterol (non-hydrogen atoms) and β~2~AR (backbone atoms of transmembrane region) separately.

Cholesterol occupancy time per residue {#s4-7}
--------------------------------------

A residue of β~2~AR was considered to be in contact with cholesterol, when any of its non-hydrogen atoms was within ≤0.5 nm of any heavy atom of cholesterol. The total occupancy time was then normalized over the entire length of a simulation, i.e., an occupancy time of one means that the particular residue of β~2~AR was in contact with cholesterol throughout the simulation, whereas a value of zero means no contact. The calculated total occupancy time per residue of β~2~AR was mapped onto the receptor's surface to highlight the regions of β~2~AR involved in cholesterol binding.

Sequence alignment at cholesterol-binding sites {#s4-8}
-----------------------------------------------

We analyzed amino acid sequences of β~2~AR orthologues from the available databases. We used the PhylomeDB server (<http://phylomedb.org/>) ([@bib24]) for finding orthologues and Clustal Omega (<http://www.ebi.ac.uk/Tools/msa/clustalo/>) ([@bib62]) for sequence alignment. The amino acid residues of β~2~AR segments constituting the cholesterol binding sites as obtained from our simulations were used for the set of sequences obtained ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}, [Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}, [Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}). The sequences in question belong to diverse species, such as insects, fish, birds, reptile, mammals, etc.

Lipid tail order parameter {#s4-9}
--------------------------

The order parameter of lipid acyl chains was calculated using :$$S_{\text{CD}} = \left\langle {\frac{3}{2}\ \left( {\cos^{2\ }\theta_{i}} \right) - \ \frac{1}{2}} \right\rangle$$

where *θ~i~* is the angle between a C-D bond (C-H in simulations) of the *i*^th^ carbon atom and the bilayer normal. The angular brackets denote averaging over time and molecules in a bilayer.

Bilayer thickness {#s4-10}
-----------------

Bilayer thickness was defined as the distance between the average planes formed by phosphorous atoms in the two bilayer leaflets. We used the g_lomepro tool ([@bib15]) to generate the 2D distribution of bilayer thickness.

Lifetime of cholesterol binding {#s4-11}
-------------------------------

For the calculation of the lifetime of cholesterol bound to the cholesterol interaction sites on the receptor surface, we first monitored the binding/unbinding events of each individual cholesterol molecule along the simulation trajectory. A cholesterol molecule was considered bound when any of its heavy atoms came within ≤0.5 nm from an interaction site. To define the three major interaction sites on the β~2~AR surface, we used the amino acid residues (with contact fraction ≥ 0.4) as shown in [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}. The time series was then additionally smoothed (over one ns time windows) to discard very rapid 'leave and return' motions of cholesterol that take place due to thermal fluctuations. Given that lateral diffusion of lipids at the protein surface is very slow, and the lipids essentially do not move at all during a 1-ns time window, these fluctuations were then taken care of by the smoothing procedure. We then calculated the normalized time correlation function (to describe the time-dependent probability of cholesterol that is next to the receptor to stay in contact with the receptor) over all individual cholesterol binding/unbinding events occurred in all independent simulation trajectories for all cholesterol molecules present in a system at a given cholesterol concentration ([@bib2]; [@bib23]).

Equilibration and error bar estimation associated with analysis {#s4-12}
---------------------------------------------------------------

For all analysis to measure time-averaged properties, the first 100 ns of production simulations were excluded from the calculation. Error bars were estimated through standard error, calculated by dividing the standard deviation of a given data set with the square root of its sample size ([@bib45]; [@bib36]). We used the g_analyze tool of GROMACS for error estimation.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Mechanism of allosteric regulation of β2-adrenergic receptor by cholesterol\" for consideration by *eLife*. Your article has been favorably evaluated by Arup Chakraborty (Senior Editor) and two reviewers, one of whom, Nir Ben-Tal (Reviewer \#1), is a member of our Board of Reviewing Editors.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The effects of membrane lipids on the structural and dynamic properties of membrane-bound proteins, as well as on their biological function, has been the subject of numerous studies. Cholesterol constitutes a particularly interesting example, as it has a complex effect on membrane structure and is also known to bind specifically to many membrane proteins. One such case is the β2-adrenergic receptor (β2-AR), to which cholesterol molecules have been shown to bind specifically. Moreover, cholesterol has been found to improve the stability, ligand binding, and signaling properties of the β2-AR. However, the mechanisms underlying these effects have never been explained in detail, and it is unclear whether cholesterol acts directly or by changing membrane properties like thickness or order. Aside of the academic interest in understanding how cholesterol modulates GPCR action, this issue is also important for the pharmaceutical industry. GPCRs constitute a major target for pharmaceutical drugs and there is a growing interest in finding molecules that can modulate GPCR activity by binding to allosteric sites.

In the current project, Vattulainen et al. studied the effect of cholesterol on the structural and dynamic properties of the β2-AR using extensive MD simulations. The simulations predicted three main cholesterol binding sites. The first (IC1) is in agreement with the crystal structures of the β2-AR, and is at the general area of a known conserved cholesterol-binding motif (CCM). The second binding site (IC2) is undocumented, and the third (EC1) is in agreement with the crystal structure of the adenosine 2A receptor. While the validity of EC1 and IC2 as specific cholesterol binding sites is yet to be confirmed, the fact that the well-documented IC1 has also been predicted by the same simulations is encouraging. Furthermore, EC1 and IC2, if valid, can be used as potential target sites for GPCR-specific drugs.

The simulations also predicted two cholesterol-induced effects on the β2-AR. The first is a general restriction of the inherent dynamics of the protein. This effect was not observed when the general properties of the membrane were changed in the absence of cholesterol, and thus, the authors concluded that this effect is specific. The second cholesterol-induced effect predicted by the simulation appeared in the second binding site, IC2. There, cholesterol was predicted to push the intracellular end of TM6 more towards the core of the helical bundle, and prevented the outward movement of this helix. This effect is particularly interesting, as the outward movement of TM6 is associated with GPCR activation, and creates the binding site for the receptor\'s cognate G-protein. The restriction of TM6 movement by cholesterol is a potentially important allosteric effect, which again, can be used to modulate GPCR activity.

This is an important project and the manuscript reads well, however, a number of outstanding issues, listed below, should be addressed before decision can be made about publication.

Essential revisions:

1\) The general restriction of β2-AR dynamics by cholesterol is rather obvious considering the rigid structure of cholesterol; this rigidity would restrict the dynamics of any molecule bound to cholesterol, be it a neighboring membrane lipid or a protein. Having said that, the fact that cholesterol analogues had a weaker effect on protein dynamics despite their rigid structure suggests that additional factors are in play. Perhaps this issue could be explored in greater detail to decipher the energy determinants and physicochemical underlines.

2\) A discussion of the effect of cholesterol binding to the first binding site (IC1) is missing. This site resides in a cleft created by TMs 1-4 and contains the conserved cholesterol consensus motif (CCM). The conservation of the CCM has implicated it as a possible allosteric site in class A GPCRs. Since the current study focusses on possible allosteric effects of cholesterol, the neglect of IC1 in the analysis of the results seems odd. Perhaps the authors can extract this information from the existing simulations.

3\) Furthermore, the results could be correlated with evolutionary data (e.g., using ConSurf). The anticipation is that biologically relevant binding sites would be shared among other GPCRs (orthologues at the very least), which implies that the binding residues should be evolutionarily conserved.

4\) [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}: That the shape of the distances distribution changes with cholesterol concentration in a non-monotonic manner is of concern. Maybe in spite of the long simulation time the results are still not converged in all ranges?

5\) This has implications on the main research question here, i.e., whether cholesterol affects the conformational changes of the receptor directly or via general effect on membrane properties. The authors argue that the distribution of receptor\' conformations when cholesterol binds the receptor directly ([Figure 1](#fig1){ref-type="fig"}) is markedly different in comparison to when it does not ([Figure 3](#fig3){ref-type="fig"}). However, to me the difference is small, and in view of the non-monotonic behavior mentioned above, the conclusion might be erroneous.

6\) While the focus here is on inactivation it would be nice to show also activation for completeness.

7\) In the Introduction -- we would value a little more background on what is known of the effect of cholesterol on GPCR and specifically β2AdR function. The Introduction says that cholesterol likely interacts with GPCRs and \'has been shown to influence the ligand binding and signaling properties of β2AR\'. This is a bit vague given this underlies the whole of the study presented here. Or perhaps not much is known experimentally, in which case to what extent can one formulate a clear hypothesis to be tested via simulation?

8\) Introduction, last paragraph. The \'physiological\' concentration of cholesterol is given as 10 mol%; Sampaio et al. says cholesterol concentration in e.g. epithelial cell membranes is more like 25 to 30 mol% (Sampaio et al., 2011, PNAS).

9\) Subsection "Membrane-mediated interactions not the key": the authors show quite conclusively that the effects of cholesterol on the conformational dynamics of the receptor and are not due simply to a change in the physical state of the surrounding bilayer. A clinching test would be to place cholesterol at the binding sites (perhaps by taking a snapshot from the high cholesterol simulation), then place the receptor/cholesterol complex in a cholesterol free membrane and see how the conformational dynamics of the protein change as the cholesterol is release. Has this been done? From the discussion of binding lifetimes (subsection "Binding lifetime depends on cholesterol"), the bound cholesterols might dissociate on a 0.1 µs timescale. Indeed, is this the simulation in [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"} (it is not clear -- [Table 1](#tbl1){ref-type="table"} is a bit impenetrable)? And if so, what is the time course for unbinding of the cholesterols? This needs to be explored/explained in more detail.

10\) Subsection "Cholesterol analogues interact with β2AR". Are there any experimental data for the specificity of the cholesterol effects on β2AdR function?

11\) The Discussion could perhaps be a bit tighter -- to some extent it re-iterates what has been said earlier.

10.7554/eLife.18432.032

Author response

*Essential revisions:*

*1) The general restriction of β2-AR dynamics by cholesterol is rather obvious considering the rigid structure of cholesterol; this rigidity would restrict the dynamics of any molecule bound to cholesterol, be it a neighboring membrane lipid or a protein. Having said that, the fact that cholesterol analogues had a weaker effect on protein dynamics despite their rigid structure suggests that additional factors are in play. Perhaps this issue could be explored in greater detail to decipher the energy determinants and physicochemical underlines.*

Our results suggest that the restriction to β~2~AR dynamics arises from the binding of cholesterol to specific interaction sites on the receptor surface. Cholesterol analogues, although being structurally very similar to cholesterol, induce weaker effects. We quantified this as follows.

We found that while both cholesterol and its analogues have a rigid ring structure, their different chemical compositions (such as the esterified succinic acid group in cholesteryl hemisuccinate (CHS) compared to the hydroxyl group in cholesterol (at the 3β position), or the additional hydroxyl groups in oxysterols not found in cholesterol) influence their occupancy as well as the strength of binding to the specific interaction sites. To explore this in more detail, we calculated the total van der Waals (vdW) interaction energy as well as the number of contacts between cholesterol and β~2~AR, when cholesterol is in the IC1, IC2, or EC1 binding site (please see [Table 2](#tbl2){ref-type="table"}). Similar calculations were carried out for the cholesterol analogues. Given that the van der Waals energy is a short-range interaction, it reflects how strongly the two molecules are in contact and therefore serves as an excellent measure for the gravity of lipid-protein binding in the binding site. The results presented in [Table 2](#tbl2){ref-type="table"} show without doubt that the van der Waals interaction of cholesterol with β~2~AR is substantially stronger than in the case of CHS or the oxysterols.

The new results show that among the three major interaction sites, the binding of CHS at IC1 is much weaker than that of cholesterol. At IC2 the strength of interaction of CHS and cholesterol are comparable. Meanwhile, the extracellular EC1 site remains unoccupied by CHS indicating the binding energy to be low. As to the two oxysterols considered in our study, 4β-OH-Chol interacts with β~2~AR only at EC1 and the interaction is weak. 27-OH-Chol binds at EC1 as tightly as cholesterol, but its interaction at the two other binding sites (IC1 and IC2) is much weaker than in the case of cholesterol. Concluding, CHS interacts at IC2 as strongly as cholesterol but its interactions at IC1 and EC1 are negligible compared to those of cholesterol. The oxysterol 27-OH-Chol interacts at EC1 as strongly as cholesterol but its interactions at IC1 and IC2 are negligible compared to those of cholesterol. The oxysterol 4β-OH-Chol does not interact with β~2~AR to a significant degree.

Consistently, we earlier found that CHS restricts the dynamics of the β~2~AR G protein binding site similarly as cholesterol (L~G~in[Figure 2---figure supplement 9C, D](#fig2s9){ref-type="fig"}), which supports our hypothesis that the binding of cholesterol or cholesterol-like molecules at IC2 (composed of intracellular ends of H5 and H6) suppresses the dynamics at the G protein binding site by suppressing the dynamics of respective helices. Similarly as EC1 remains completely unoccupied by CHS, it cannot restrict the dynamics of the extracellular ligand-binding site of the receptor (L~L~in [Figure 2---figure supplement 9C, D](#fig2s9){ref-type="fig"}).

These data can be considered in the context of molecular structures. In CHS, the difference compared to cholesterol is the additional chain coupled to cholesterol via an ester bond ([Figure 2---figure supplement 6A](#fig2s6){ref-type="fig"}). Based on our results this additional chain does not interfere binding at IC2, but it does interfere the binding at IC1 and EC1. In 27-OH-Chol, the oxidation has taken place in the short acyl chain that is the terminal subunit of the molecule. This does not interfere the binding at EC1 but does alter the binding at IC1 and IC2. Finally, in 4β-OH-Chol, the oxidation has taken place in the rigid steroid moiety, making the α-side of the molecule rougher. In cholesterol, the α-side is exceptionally flat. Given this change in surface roughness, and the importance of the surface-surface contact in lipid-β~2~AR binding in the binding site, it is quite obvious why this oxysterol does not bind with any of the cholesterol binding sites (IC1, IC2, EC1).

The new results confirm that the binding of cholesterol or cholesterol-like molecules at the specific interaction sites restrict the conformational fluctuation of β~2~AR -- tighter binding suppresses β~2~AR dynamics considerably, and the effect of cholesterol is the strongest. The new results also provide a more solid structural basis to understand why the binding of cholesterol with β~2~AR is superior compared to CHS or the oxysterols.

Based on the above, we have done the following revisions and additions:

We have discussed the above ideas (Section: Cholesterol analogues interact with β~2~AR);

We have presented [Table 2](#tbl2){ref-type="table"} and discussed its results.

*2) A discussion of the effect of cholesterol binding to the first binding site (IC1) is missing. This site resides in a cleft created by TMs 1-4 and contains the conserved cholesterol consensus motif (CCM). The conservation of the CCM has implicated it as a possible allosteric site in class A GPCRs. Since the current study focusses on possible allosteric effects of cholesterol, the neglect of IC1 in the analysis of the results seems odd. Perhaps the authors can extract this information from the existing simulations.*

The X-ray crystal structure (PDB id: 3D4S) of β~2~AR has established a specific cholesterol-binding site between the intracellular segments of helices (H) 1, 2, 3, and 4 (Gilchrist, 2010). The given study defines a cholesterol consensus motif (CCM) \[4.39-4.43(R,K)\]---\[4.50(W,Y)\]---\[4.46(I,V,L)\]---\[2.41(F,Y)\], which predicts cholesterol binding for 44% of human class A receptors (Gilchrist, 2010). Our present simulation study reproduced cholesterol binding at this interaction site (named in our paper as IC1) and satisfied the condition of strict-CCM binding, where the conserved residues (R151^4.43^, W158^4.50,^I154^4.46^, andY70^2.41^) participated in cholesterol binding ([Author response image 1](#fig6){ref-type="fig"}). The close agreement between our simulation results and the experimental prediction strengthens the view that the simulation approach we have used is valid.10.7554/eLife.18432.026Author response image 1.Specific cholesterol binding site in β~2~AR with CCM displayed with side chain positions of conserved amino acid residues, as found in (**A**) the crystal structure (1) and (**B**) during our simulation.In the simulation snapshot, residues are colored according to their strength of interaction with cholesterol (red represents the weakest and blue represents the strongest interaction).**DOI:** [http://dx.doi.org/10.7554/eLife.18432.026](10.7554/eLife.18432.026)

The physiological relevance of specific cholesterol binding at IC1 is not yet fully understood. In the article describing the crystal structure, the authors used the occluded surface area method to analyze internal packing of helices (Gilchrist, 2010). The study showed that cholesterol increases the packing of H4, indicating decreasing mobility (Gilchrist, 2010). The effect was suggested to be due to the binding of cholesterol at IC1, where H4 establishes major binding interactions ([Author response image 1](#fig6){ref-type="fig"}). From the simulation trajectory we calculated the standard deviation of H4 fluctuations, when IC1 is either occupied or unoccupied by cholesterol ([Author response image 2](#fig7){ref-type="fig"}). Our results show that the fluctuations of H4 around its average position are more suppressed when cholesterol is bound to IC1. This result is in agreement with experimental findings. While H4 is not one of the strongest points of β~2~AR fold, its decreased mobility may account for the enhanced stability of the receptor. We did not observe similar stabilizing effects of cholesterol binding at IC1 on the helices H1-H3. Finally, a recent simulation study reported a correlation between cholesterol occupancy at IC1 and β~2~AR dimerization (Lefkowitz, 2000). This study showed that cholesterol occupancy at H4 restricts its participation in dimer interface formation and subsequently stabilizes the dimer interface with H1 and H2 instead of H4 and H5 (Lefkowitz, 2000).10.7554/eLife.18432.027Author response image 2.For the time-dependent distance betweenH4 and its average position, as the H4 helix fluctuates around its average location, shown here are results for the standard deviation of the distance fluctuations.Data are given for cases, where IC1 is occupied (blue) or unoccupied (orange) by cholesterol.**DOI:** [http://dx.doi.org/10.7554/eLife.18432.027](10.7554/eLife.18432.027)

We move on to discuss if there is any impact of IC1 on the observed conformational change of β~2~AR reported in our work. To decouple the effect of IC1 from the two other binding sites, we consider the following cases. Our results show that CHS interacts at IC2 as strongly as cholesterol ([Table 2](#tbl2){ref-type="table"}). In systems with 10 mol% CHS, we observed a high CHS density at IC2, but not at IC1 or EC1 ([Figure 2---figure supplement 8C, D](#fig2s8){ref-type="fig"}). In the system with 40 mol% CHS, in addition to a high CHS density at IC2, IC1 is also occasionally occupied by CHS, while EC1 remains unoccupied ([Figure 2---figure supplement 8E, F](#fig2s8){ref-type="fig"}). In either of these cases, CHS restricts the dynamics of the G protein-binding site similarly to the extent of cholesterol ([Figure 1---figure supplement 1C, E](#fig1s1){ref-type="fig"} and [Figure 2---figure supplement 9C, D](#fig2s9){ref-type="fig"}), irrespective of whether IC1 is occupied or unoccupied by cholesterol. The result indicates that sterol occupancy at IC2, but not at IC1, is crucial for controlling the dynamics of the G protein binding site, calculated by the displacement of the intracellular part of H6. This conclusion is further supported by the observation that in the presence of 5 mol% cholesterol, β~2~AR exhibits large fluctuations at the G protein binding site ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"} and [Author response image 3](#fig8){ref-type="fig"}), where IC1 is occupied by cholesterol but IC2 remains unoccupied ([Figure 2---figure supplement 5](#fig2s5){ref-type="fig"}(top panel)). In bilayers with CHS, no CHS was observed at the extracellular binding site EC1. Consequently, in these systems β~2~AR shows large fluctuations at the extracellular ligand binding site, irrespective of the high CHS occupancy at IC2 and also at IC1 for systems with 40 mol% CHS.

Altogether these results suggest that IC1, located at the intracellular surface cleft between H1-H4, does not show much influence on the mobility of H5 and H6, which play a major role in determining the conformational dynamics of β~2~AR.

Based on the above, we have done the following revisions and additions:

We have discussed the above ideas (Section: Discussion);

We have added [Figure 2---figure supplement 10](#fig2s10){ref-type="fig"}and discussed this new data;

We have included two new videos ([Video 1](#media1){ref-type="other"} and [Video 2](#media2){ref-type="other"} (related to [Figure 5](#fig5){ref-type="fig"})).

*3) Furthermore, the results could be correlated with evolutionary data (e.g., using ConSurf). The anticipation is that biologically relevant binding sites would be shared among other GPCRs (orthologues at the very least), which implies that the binding residues should be evolutionarily conserved.*

Our simulations suggest three main binding sites of cholesterol on β~2~AR ([Figure 2](#fig2){ref-type="fig"}). One of these sites (IC1), located at the intracellular surface cleft between H1-4, matches very well the recently reported crystal structure of β~2~AR (Gilchrist, 2010). This site contains a cholesterol consensus motif (CCM) with the sequence \[4.39-4.43(R,K)\]---\[4.50(W,Y)\]---\[4.46(I,V,L)\]---\[2.41(F,Y)\]. As also discussed in the previous point, our simulations reproduce interactions between these conserved amino acid residues and cholesterol ([Author response image 1](#fig6){ref-type="fig"}) that are important in binding cholesterol at IC1.44% of human class A receptors are predicted to bind cholesterol at the same site as β~2~AR (see [Figure 5](#fig5){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"} of Gilchrist, 2010). In addition to IC1, our simulations proposed two other cholesterol interaction sites (IC2 and EC1) on β~2~AR. EC1 is in agreement with the location of cholesterol found in the crystal structure of the adenosine receptor A~2A~AR (Manglik and Kobilka, 2014).

As suggested by the reviewers, in order to examine whether our predicted β~2~AR cholesterol binding sites are conserved during the evolution of the receptor, we analyzed amino acid sequences of β~2~AR orthologues from available databases ([Figure 2---figure supplements 2](#fig2s2){ref-type="fig"}, [3](#fig2s3){ref-type="fig"}, [4](#fig2s4){ref-type="fig"}). We used the PhylomeDB server (<http://phylomedb.org/>) (Kobilka, 2013) for finding orthologues and Clustal Omega (<http://www.ebi.ac.uk/Tools/msa/clustalo/>) (Cherezov et al., 2007) for sequence alignment. The amino acid residues of β~2~AR segments constituting the cholesterol binding sites as obtained from our simulations are used for the set of sequences obtained ([Figure 2---figure supplements 2](#fig2s2){ref-type="fig"}, [3](#fig2s3){ref-type="fig"}, [4](#fig2s4){ref-type="fig"}). The following sequences belong to diverse species, such as insects, fish, birds, reptile, mammals, etc. The alignments show that the cholesterol binding residues of the three interaction sites are conserved in most of the species. Therefore, it appears that these cholesterol-binding sites are evolutionarily conserved in β~2~AR.

Based on the above, we have done the following revisions and additions to the paper:

We have discussed the above ideas in the main paper (Section: Specific binding of cholesterol);

We have added [Figure 2---figure supplements 2](#fig2s2){ref-type="fig"}, [3](#fig2s3){ref-type="fig"}, [4](#fig2s4){ref-type="fig"}, where we provide this new data in full.

*4) [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}: That the shape of the distances distribution changes with cholesterol concentration in a non-monotonic manner is of concern. Maybe in spite of the long simulation time the results are still not converged in all ranges?*

We are afraid that there was a misunderstanding of the data shown in the original manuscript. We consider this possibility in the end of this point, however let us first discuss the data and show that their cholesterol concentration dependence is systematic/monotonic, as expected.

In [Author response image 3](#fig8){ref-type="fig"} we depict the distributions of L~L~ (width of the ligand binding site) and L~G~ (width of the G protein interface) distances separately for each individual trajectory and for all the different cholesterol concentrations (0-40 mol%). These data correspond to the L~L~ vs. L~G~ distance distributions shown in [Figure 1---figure supplement 1A-E](#fig1s1){ref-type="fig"}. It is apparent from [Author response image 3](#fig8){ref-type="fig"} that the distributions of both L~L~ and L~G~ are broad in the absence of cholesterol, and also at a very low cholesterol concentration (2 mol%), indicating that for low cholesterol concentrations the β~2~AR receptor undergoes continuous conformational fluctuations between "wide ligand-binding site/narrow G protein-binding site" and "narrow ligand-binding site/wide G protein binding site". However, the distributions become more and more narrow with increasing cholesterol concentration. At cholesterol concentrations above about 10 mol%, one finds sharper distributions with a single peak, reflecting the confinement of the receptor in a particular conformational state. Moreover, [Author response image 3](#fig8){ref-type="fig"} shows that in individual simulations for a given cholesterol concentration, the receptor samples essentially similar states, indicating quite complete convergence of the present simulation results. The results therefore confirm a systematic/monotonic effect of cholesterol concentration on the β~2~AR conformational distribution.

Further, we have binned the 2D conformational distance data (shown, e.g., in [Figures 1B and 1C](#fig1){ref-type="fig"}in the main text) to a 2D histogram, and then counted its 'area\' by calculating the number of bins that had a non-zero value. The results depicted in [Author response image 4](#fig9){ref-type="fig"} show that for increasing cholesterol concentration, the area covered by the (L~L~, L~G~) conformational distribution decreases, in line with the data shown in Autghor response [image 3](#fig3){ref-type="fig"}. To make sure that this result is not compromised by bins where the value of the probability of being in a given (L~L~, L~G~)-state is very low, we repeated the analysis by disregarding the bins whose occupancy was less than 1% of the maximum value in the 2D distribution. The latter calculation (cutoff 0.01 x P~max~ shown in [Author response image 4](#fig9){ref-type="fig"}) does not affect the result: the effect of cholesterol is systematic ([Author response image 4](#fig9){ref-type="fig"}).

Therefore, the data presented here show that the conformational distribution of the receptor determined as a function of L~L~ and L~G~ distances changes in a systematic/monotonic manner with increasing cholesterol concentration from 0 to 40 mol%. These concentration values correspond to the distance distributions presented in panels A-E(earlier B-F) of [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}.

Panel F(earlier A) of [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}is an exception, however here the initial configuration of the simulated system was distinctly different compared to the other simulated systems. [Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}(earlier 1A) describes a situation, where 8 cholesterol molecules were initially (at time zero of the simulation) bound at the 8 interaction sites on β~2~AR that were predicted by our simulations and previous experimental data, while the rest of the membrane system had no cholesterol. Therefore, in this system, at large times in the multi-microsecond scales, all or at least most of the cholesterol molecules were no longer bound to β~2~AR and instead they resides in the membrane far from the receptor -- therefore at long times this system describes cholesterol-poor conditions. We consider that since this background was not described to a sufficient degree in the original paper, the reviewers unfortunately misunderstood the situation described by this system. A detailed discussion of this system and its results are given in the point 9 below.

Based on the above, we have clarified the concerns and questions presented. However, we concluded that the new results ([Author response image 3](#fig8){ref-type="fig"} and [Author response image 4](#fig9){ref-type="fig"}) do not add significant new insight to the paper; therefore, they have not been included to the paper.10.7554/eLife.18432.028Author response image 3.Distributions of L~L~ and L~G~ distances from individual trajectories (shown in different colors) for various cholesterol concentrations.**DOI:** [http://dx.doi.org/10.7554/eLife.18432.028](10.7554/eLife.18432.028)10.7554/eLife.18432.029Author response image 4.Area in the 2D histogram visited by the receptor conformations.The bin edge length was set to 0.1 Å in both dimensions.**DOI:** [http://dx.doi.org/10.7554/eLife.18432.029](10.7554/eLife.18432.029)

*5) This has implications on the main research question here, i.e., whether cholesterol affects the conformational changes of the receptor directly or via general effect on membrane properties. The authors argue that the distribution of receptor\' conformations when cholesterol binds the receptor directly ([Figure 1](#fig1){ref-type="fig"}) is markedly different in comparison to when it does not ([Figure 3](#fig3){ref-type="fig"}). However, to me the difference is small, and in view of the non-monotonic behavior mentioned above, the conclusion might be erroneous.*

Please see our answer above regarding the "non-monotonic" behavior. [Figure 1C](#fig1){ref-type="fig"} represents the distribution of the receptor's conformation in the presence of 10 mol% cholesterol when cholesterol binds to the receptor directly. As we discussed in the earlier point, here the distribution is restricted to one particular conformation with L~L~ \~ 13 Å and L~G~ \~ 9.5 Å. The receptor samples a similar conformational space at higher cholesterol concentrations ([Figure 1---figure supplement 1C-E](#fig1s1){ref-type="fig"} and [Author response image 3](#fig8){ref-type="fig"}).

On the other hand, in the absence of cholesterol, β~2~AR samples a much broader conformational space ([Figure 1B](#fig1){ref-type="fig"} and [Author response image 3](#fig8){ref-type="fig"}) with L~L~ ranging between \~11-17 Å and L~G~ ranging between \~7-13 Å).

Importantly, the broad conformational distribution of β~2~AR found under cholesterol-poor conditions is also observed in cholesterol-free bilayers whose physical properties are consistent with cholesterol-rich bilayers (but without cholesterol). First, cholesterol is known to increase membrane thickness significantly. We induced this effect with long-chain PC lipids that give rise to a thick membrane and found (see [Figure 4A](#fig4){ref-type="fig"}) (earlier [Figure 3](#fig3){ref-type="fig"}) that in this system L~L~ fluctuates strongly between \~11-16.5 Å and L~G~ varies between \~7-12.5 Å. This implies that a thick membrane does not induce the restricted conformational behavior we found in cholesterol-rich bilayer ([Figure 1C](#fig1){ref-type="fig"}). Second, cholesterol is known to order lipid membranes significantly. To test this membrane-mediated effect, we used pyrene instead of cholesterol to increase membrane order to a level that matches the membrane order found with 10 mol% of cholesterol. The results ([Figure 4C](#fig4){ref-type="fig"}) show L~L~ to range between \~9-17.5 Å and L~G~ to vary between \~7-13.5 Å, therefore the receptor's conformational fluctuations match the data found in the absence of cholesterol. This implies that membrane-mediated interactions do not cause the restricted conformational behavior we found with cholesterol.

Altogether, the data show that when cholesterol concentration is increased from low to high (from about zero to 10 mol%), the conformational behavior of β~2~AR is altered significantly. At small cholesterol concentrations, the ligand and the G protein binding sites of β~2~AR fluctuate between wide and narrow states, while at high cholesterol concentrations the β~2~AR conformation (and the ligand and the G protein binding sites) are fixed to a single state. These trends are systematic and consistent as we increase cholesterol concentration from zero to 40 mol%. These data were consistent when we repeated the simulations for every cholesterol concentration many times.

Based on the above, we have done the following revisions:

We have clarified the concern as to the assumed non-monotonic behavior ([Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}, [Table 1](#tbl1){ref-type="table"});

We have included two new videos ([Video 1](#media1){ref-type="other"} and [Video 2](#media2){ref-type="other"} (related to [Figure 5](#fig5){ref-type="fig"})).

*6) While the focus here is on inactivation it would be nice to show also activation for completeness.*

Studying activation, i.e., transition from the inactive to the active sate β~2~AR is beyond the present work given that the timescale of the activation process is likely milliseconds. Nonetheless, we followed the reviewers' recommendation and carried out an additional extensive set of simulations for the active-state receptor.

We studied the effect of cholesterol on the conformation of the active state β~2~AR in apo form and in the absence of the G protein (Hanson et al., 2008). We conducted replicate unbiased atomistic MD simulations of the active state β~2~AR embedded in a DOPC bilayer with 0 and 40 mol% cholesterol (three independent 2.5 μs simulations for each system, see [Table 1](#tbl1){ref-type="table"}). In the active form, the intracellular end of H6 is splayed outward from the helical bundle providing room for the G protein ([Author response image 5A](#fig10){ref-type="fig"}).

In the absence of cholesterol (0 mol%), we observed inward swinging of H6 towards H3 (observed in 2 out of 3 replicas). As shown in [Author response image 5B, E](#fig10){ref-type="fig"}, the intracellular end of H6 spontaneously approaches H3 with L~G~ dropping from 18.97 Å in the starting active conformation to \~11.5 Å that matches the crystallographically observed inactive conformation of β~2~AR (L~G~ \~11 Å). Such spontaneous deactivation of the receptor in the absence of the intracellular binding partner is in agreement with recent simulations (Rasmussen et al., 2011; Nygaard et al., 2013) and experimental studies (Dror et al., 2009).

In the presence of cholesterol (40 mol%), we observed that the active-like open conformation (without G protein) is stable during the simulations ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). As shown in [Author response image 5C, E](#fig10){ref-type="fig"},the L~G~ value remains stable \~16.5 Å and no deactivation is observed unlike in cholesterol-free systems. Interestingly, we found a high cholesterol density at the IC2 interaction site located at the cleft between the intracellular segments of H5-H6 ([Author response image 5C, D, F](#fig10){ref-type="fig"}). Cholesterol bound at IC2 acts as a spacer between H5-H6 and restricts the movement of H6, thereby stabilizing the open active-like conformation of the receptor ([Author response image 5C, D](#fig10){ref-type="fig"}).

These results for the active state β~2~AR support our previous conclusion that cholesterol restricts the conformational dynamics of the receptor by binding at specific interaction sites. Altogether, our results (based on both inactive and active-state β~2~AR conformations) suggest that specific interactions of cholesterol with β~2~AR govern changes between the receptor's different conformational states, which in turn affect receptor activation. Moreover, the results highlight the importance of IC2: cholesterol binding at IC2 in both inactive and active conformational states of β~2~AR as found in our simulations indicates the significant biological relevance of this interaction site.

Based on the above, we have done the following revisions and additions:

We have discussed the above ideas in the paper (Sections: Cholesterol restricts β~2~AR conformation; Discussion) and shown as a new [Figure 3](#fig3){ref-type="fig"};

We have added [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}.10.7554/eLife.18432.030Author response image 5.Cytosolic view of β~2~AR (**A**) in the beginning of simulation (active state) as well as in representative simulation snapshots in (**B**) a DOPC bilayer and (**C**) in the presence of 40 mol% cholesterol.The dotted line represents the distance between the Cα atoms of R131^3.50^--E268^6.30^ (defined as L~G~) used to measure the fluctuation at the G protein binding site. (**D**) Simulation snapshot (in the presence of 40 mol% cholesterol) showing cholesterol binding at the interaction sites of β~2~AR. (**E**) The time evolution of L~G~ in systems with 0 (light red) and 40 mol% cholesterol (light blue). Corresponding 50-point running averages are shown in dark colors. (**F**) 2D number densities of cholesterol (Chol) around β~2~AR (cytosolic view). The transmembrane regions of β~2~AR are shown in gray scale (the darker the color, the higher is the number density), and they are numbered accordingly to show the locations of the individual helices (H1-H7).**DOI:** [http://dx.doi.org/10.7554/eLife.18432.030](10.7554/eLife.18432.030)

*7) In the Introduction we would value a little more background on what is known of the effect of cholesterol on GPCR and specifically β2AdR function. The Introduction says that cholesterol likely interacts with GPCRs and \'has been shown to influence the ligand binding and signaling properties of β2AR\'. This is a bit vague given this underlies the whole of the study presented here. Or perhaps not much is known experimentally, in which case to what extent can one formulate a clear hypothesis to be tested via simulation?*

β~2~AR belongs to the family of class A GPCRs. GPCRs belonging to this class show a high structural similarity and functional diversity. The literature reporting on the specific functional role of cholesterol and other lipids is extensive (Ozcan et al., 2013; Dror et al., 2011). Reportedly cholesterol has been shown to affect the conformation (Oates and Watta, 2011; Lingwood and Simons, 2010) and function (Ozcan et al., 2013; Oates and Watta, 2011;Allen, Halverson-Tamboli and Resenick, 2007; Contreras et al., 2012; Coskun et al., 2011) of many GPCRs. Experimental data have been published that cholesterol binds specifically to β~2~AR (Gilchrist, 2010; Neale et al., 2015), and it has been experimentally shown that cholesterol binding to β~2~AR changes its structural properties (Gilchrist, 2010; Dawaliby et al., 2016). Since structure and function of GPCRs are closely related one may thus expect that cholesterol binding specifically to β~2~AR changes also the functional properties of the receptor. Indeed a few experimental papers have been published which indicate that cholesterol also has a functional role (Paila and Chattopadhyay, 2009; Gimpl, Burger and Fahrenholz, 1997). Thus, in our study we wanted to understand a molecular dynamics basis where and how cholesterol binds to β~2~AR and which are the possible structural and functional effects.

Based on the above, we have done the following revisions:

We have revised the Introduction accordingly, together with related new references.

*8) Introduction, last paragraph. The \'physiological\' concentration of cholesterol is given as 10 mol%; Sampaio et al. says cholesterol concentration in e.g. epithelial cell membranes is more like 25 to 30 mol% (Sampaio et al., 2011, PNAS).*

We have removed the term "physiological" and modified the manuscript accordingly.

*9) Subsection "Membrane-mediated interactions not the key": the authors show quite conclusively that the effects of cholesterol on the conformational dynamics of the receptor and are not due simply to a change in the physical state of the surrounding bilayer. A clinching test would be to place cholesterol at the binding sites (perhaps by taking a snapshot from the high cholesterol simulation), then place the receptor/cholesterol complex in a cholesterol free membrane and see how the conformational dynamics of the protein change as the cholesterol is release. Has this been done? From the discussion of binding lifetimes (subsection "Binding lifetime depends on cholesterol"), the bound cholesterols might dissociate on a 0.1 µs timescale. Indeed, is this the simulation in [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"} (it is not clear -- [Table 1](#tbl1){ref-type="table"} is a bit impenetrable)? And if so, what is the time course for unbinding of the cholesterols? This needs to be explored/explained in more detail.*

The reviewers correctly sensed that we have already done this test. Let us here explain this matter more clearly.

We performed simulations (3 replicas) where 8 cholesterol molecules were initially placed at the binding sites of β~2~AR that were predicted by our simulations (snapshot in [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}); then we placed the receptor/cholesterol complex in a cholesterol-free membrane ("Chol-Bound" trajectory in [Table 1](#tbl1){ref-type="table"}). The conformational distribution of β~2~AR is shown in [Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}(earlier 1A, as correctly pointed out by the reviewer in a previous point). [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"} shows the time profile of unbinding events of cholesterol. From a majority of the binding sites cholesterol leaves very quickly in a timescale of tens to hundreds of nanoseconds ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), similarly to the short binding lifetime observed for cholesterol-poor systems (2 mol%, [Figure 5](#fig5){ref-type="fig"}). However, there are also sites where cholesterol stays for the entire simulation time (IC1 in repeats 2 and 3, and IC2 in repeats 1 and 3) or where cholesterol is released from the receptor in μs timescale (IC3 and EC3 in repeat 1).

Although for these systems the average cholesterol concentration is low (1.9 mol%), due to the setup of the initial system configuration, the concentration of cholesterol in the annular region is high when the simulation is started. Then, as some cholesterol molecules are released from the receptor during the course of the simulations, the concentration of cholesterols bound to the receptor decreases gradually but systematically. Given this, the early-time behavior of these systems corresponds to cholesterol-rich conditions while at long times the behavior corresponds to cholesterol-poor conditions.

When we analyzed the "Chol-bound" simulations ([Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}), we found that the conformational behavior of β~2~AR changes from cholesterol-rich behavior (as in [Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}) to cholesterol-poor behavior (as in [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). However, presenting the time-dependence of the data in [Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}is not particularly useful given that the sampling within each time window would be so limited that it would be hard to see the trends easily.

Based on the above, we have done the following revisions and additions to the paper:

We have discussed this data more concretely in the paper (Section: Cholesterol restricts β~2~AR conformation), where we also clarified [Figure 1](#fig1){ref-type="fig"};

[Table 1](#tbl1){ref-type="table"} has been clarified.

*10) Subsection "Cholesterol analogues interact with β2AR". Are there any experimental data for the specificity of the cholesterol effects on β2AdR function?*

There are experimental data showing the specific role of cholesterol on β~2~AR on a functional (Paila and Chattopadhyay, 2009; Gimpl, Burger and Fahrenholz, 1997) and structural basis (Gilchrist, 2010; Dawaliby et al., 2016). The data presented in ref 19 on the influence of cholesterol manipulation on the signaling properties of β~2~AR show an inhibition of β~2~AR-associated signaling by increasing membrane cholesterol content. These are now briefly discussed in the article.

*11) The Discussion could perhaps be a bit tighter -- to some extent it re-iterates what has been said earlier.*

We have followed the advice and revised/cut the Discussion to be more solid. The total length has not decreased though, since due to the additional simulations for the active-state receptor, the further discussion on the role of cholesterol interactions with the active-state β~2~AR had to be included in the Discussion, too.

[^1]: \*In the DOPC-active and Chol40-active systems, we used the active-state conformation of the receptor as the starting structure; for all the other systems, we used the inactive conformation.

[^2]: ^†^For systems with no sterols initially bound to β~2~AR, i.e., the systems which started with a random distribution of lipids, a number of different repeat simulations for each lipid composition were performed with different initial lipid arrangements around the receptor. For systems with sterols initially bound to β~2~AR (see^d^ and BOUND), different replicas were generated with different starting velocities.

[^3]: ^‡^Listed are the simulation times of production simulations; the equilibration time of the systems (100 ns) is not included.

[^4]: ^§^In the Chol-Bound system, eight cholesterol molecules were initially (at time zero of the simulation) bound at eight binding sites predicted by the present simulations, while the rest of the system had no cholesterol at all.

[^5]: ^\*^ Shown are the total van der Waals (vdW) interaction energy and the number of contacts between cholesterol and β~2~AR, when cholesterol is in the IC1, IC2, or EC1 binding site (and similarly for the cholesterol analogues).

[^6]: ^†^ Calculations are based on systems having ≥10 mol% cholesterol. Shown here are the average values over different trajectories.
